Synopsys Inc

SNPS is in a Stage 4 decline but is mean-reversion eligible, allowing tactical buys from extreme oversold and valuation lows. Price is extended below all major EMAs with extreme OS readings, but no relief bounce has emerged. Execution should be deferred, stalking for a pullback or consolidation into the recently defended cycle low or into EMA resistance for better entry.

• ↑Q2 non-GAAP EPS $3.35 and revenue $2.28B (+41.9% YoY), beating estimates
• ↑Raised FY26 revenue guidance to $9.625–9.705 billion on strong momentum
• ↓Ongoing China restrictions may reduce revenue; IP segment in transition